GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » 3-Year Dividend Growth Rate
Switch to:

Biogen (BUE:BIIB) 3-Year Dividend Growth Rate

: 0.00% (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Biogen's Dividends per Share for the three months ended in Mar. 2023 was ARS0.00.

The historical rank and industry rank for Biogen's 3-Year Dividend Growth Rate or its related term are showing as below:

BUE:BIIB's 3-Year Dividend Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 9.60
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Biogen's Dividend Payout Ratio for the three months ended in Mar. 2023 was 0.00. As of today, Biogen's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biogen 3-Year Dividend Growth Rate Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Biogen's 3-Year Dividend Growth Rate falls in comparison to its industry or sector. The grey bar indicates the 3-Year Dividend Growth Rate's extreme value range as defined by GuruFocus.



Biogen 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


Biogen  (BUE:BIIB) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Biogen's Dividend Payout Ratio for the quarter that ended in Mar. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2023 )/ EPS without NRI (Q: Mar. 2023 )
=0/ 527.459
=0.00

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen 3-Year Dividend Growth Rate Related Terms>


Biogen (BUE:BIIB) Business Description

Biogen logo
Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines

Other Sources

Is Biogen Stock a Buy Now?

By Yahoo Finance 2023-01-26